Nonpegylated liposomal doxorubicin (nPLD) in neoadjuvant treatment of local advanced breast cancer (LABC) patients (pts)

被引：0
|
作者：
Rossi, Luigi
Tomao, Federica
Papa, Anselmo
Zoratto, Federica
Ricci, Fabio
Spinelli, Gian Paolo
Lo Russo, Giuseppe
Basso, Enrico
Caprio, Giuliana
Barberi, Simona
Verrico, Monica
Giordani, Erika
Zaccarelli, Eleonora
Rinaldi, Giulia
Stati, Valeria
Pasciuti, Giulia
Strudel, Martina
Tomao, Silverio
机构：
[1] Univ Rome, Santa Maria Goretti Hosp, Dept Medicosurg Sci & Biotechnol, Oncol Unit, Latina, Italy
[2] Dept Gynecol & Obstet, Rome, Italy
[3] Osped SM Goretti, Latina, Italy
[4] Univ Rome, Dept Expt Med & Pathol, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11514
引用
收藏
页数：1
相关论文
共 50 条
  • [21] NEOADJUVANT THERAPY OF LOCALLY ADVANCED BREAST-CANCER (LABC)
    SWAIN, S
    LIPPMAN, M
    BAGLEY, C
    SORACE, R
    WESLEY, M
    [J]. CANCER DRUG DELIVERY, 1986, 3 (01): : 55 - 55
  • [22] Neoadjuvant chemotherapy with nonpegylated liposome-encapsulated doxorubicin (NPLD) plus cyclophosphamide followed by trastuzumab plus nabpaclitaxel for HER2-positive breast cancer (BC).
    Saracchini, Silvana
    Foltran, Luisa
    Bassini, Anna
    Faro, Sandro Su
    Lorenzon, Michele
    Micheli, Elvia
    Favero, Alessandro
    Marus, Wally
    Del Conte, Alessandro
    Gusso, Giuseppina
    Manente, Stefania
    Tumolo, Salvatore
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [23] Liposomal doxorubicin significantly reduces cardiotoxicity in advanced breast cancer patients
    不详
    [J]. ONCOLOGY-NEW YORK, 2001, 15 (09): : 1135 - 1135
  • [24] Neoadjuvant capecitabine (X) plus clocetaxel (T) for patients (pts) with locally advanced breast cancer (LABC): Preliminary safety and efficacy data
    Lybaert, W.
    Wildiers, H.
    Neven, P.
    Christaens, M.-R.
    Weltens, C.
    Drijkonngen, R.
    Van Ongeval, C.
    Van Steen, A.
    Paridaens, R.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 105 - 106
  • [25] Capecitabine chemoradiation (X-RT) as neoadjuvant therapy for patients (pts) with locally advanced breast cancer (LABC) refractory to anthracyclines.
    Gaui, MF
    Amorim, G
    Arcuri, R
    Pereira, G
    Moreira, D
    Djahjah, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 52S - 52S
  • [26] Phase II multicenter study of nonpegylated liposomal doxorubicin (A) and docetaxel (T) as neoadjuvant chemotherapy in patients with stage II-IIIand inflammatory breast cancer (BC).
    Andres, R
    Garcia-Bueno, JM
    Madroñal, AMC
    Mayordomo, JI
    Centelles, IMM
    Belon, J
    Palombo, H
    Burillo, M
    Alvarez, I
    Aguirre, RLEOE
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 77S - 77S
  • [27] Neoadjuvant liposomal doxorubicin and carboplatin is effective and tolerable for the treatment of triple negative breast cancer
    Chan, N.
    Riedlinger, G. M.
    Lu, S-e
    Pham, K. T.
    Kirstein, L. J.
    Eladoumikdachi, F. G.
    George, M. A.
    Potdevin, L. B.
    Kowzun, M. J.
    Desai, S. A.
    Tang, D. M.
    Omene, C. O.
    Wong, S. T.
    Rodriguez-Rust, L.
    Kumar, S.
    Kearney, T. J.
    Liu, C.
    Ganesan, S.
    Toppmeyer, D. L.
    Hirshfield, K. M.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [28] EVALUATION OF CLINICAL CARDIOTOXICITY OF NONPEGYLATED LIPOSOMAL DOXORUBICIN IN THE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER (MBC) WHO HAD RECEIVED PRIOR ADJUVANT ANTHRACYCLINES
    Bellocco, Giuseppe
    Iannopollo, Michele
    Condemi, Giovanni
    [J]. ANNALS OF ONCOLOGY, 2009, 20
  • [29] Neoadjuvant chemotherapy with Vinorelbine and Epirubicin in locally advanced breast cancer (LABC).
    Puerto, VL
    Cardenas, J
    Lara, F
    Goana, R
    Silva, A
    Barroso, N
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 299 - 299
  • [30] Phase I Study of Nonpegylated Liposomal Doxorubicin plus Trastuzumab in Patients with HER2-Positive Breast Cancer
    Theodoulou, Maria
    Batist, Gerald
    Campos, Susana
    Winer, Eric
    Welles, Lauri
    Hudis, Clifford
    [J]. CLINICAL BREAST CANCER, 2009, 9 (02) : 101 - 107
12345